AbbVie Inc.
AbbVie Appoints New CEO and Announces 2024 Annual Meeting Results
Summary
AbbVie Inc. announced on February 20, 2024, that Robert A. Michael will succeed Richard A. Gonzalez as Chief Executive Officer, effective July 1, 2024. Richard A. Gonzalez will transition to the role of Executive Chairman of the Board. The 2024 Annual Meeting of Stockholders held on May 3, 2024, resulted in the election of Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the approval of the compensation of AbbVie's named executive officers on an advisory basis. Stockholders also voted on the frequency of future say on pay votes, opting for an annual basis until the next advisory vote required by 2030. Management's proposal to amend the certificate of incorporation to eliminate supermajority voting was not approved, nor were the stockholder proposals to implement simple majority voting and to issue annual reports on lobbying and patent process.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement